Picture loading failed.

Anti-KDR therapeutic antibody (Pre-made Ramucirumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-468-1mg 1mg 3090
GMP-Bios-ab-468-10mg 10mg 21890
GMP-Bios-ab-468-100mg 100mg 148000
GMP-Bios-ab-468-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-KDR therapeutic antibody (Pre-made Ramucirumab biosimilar,Whole mAb)
INN Name Ramucirumab
TargetKDR
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure3s34:HL/3s37:HL/3s36:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesDyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine
Conditions ApprovedColorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer
Conditions ActiveOesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer
Conditions DiscontinuedBreast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma
Development TechDyax Human Phage Display